SCHEMBL7448199

SCHEMBL7448199

C1C2CC3CC1CC(C2)C3C1CO1

nearest known ligand 0.39

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.36
CYP2A13 Q16696 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL153488 0.78 CYP2C9 (0.33) CYP2C9
SCHEMBL7608395 0.78 CYP2A13 (0.33) CYP2C9CYP2A13
SCHEMBL11941337 0.77
SCHEMBL2189873 0.73 CYP2C9 (0.50) CYP2C9CYP2A13
SCHEMBL15994525 0.71
SCHEMBL16553448 0.70
SCHEMBL14118212 0.69 HSD11B1 (0.33)
SCHEMBL12074734 0.69
SCHEMBL19223207 0.67
SCHEMBL12977163 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889901-B2 Photoacid generator, method for producing the same, and resist composition comprising the same KOREA KUMHO PETROCHEMICAL CO., LTD. 2014-11-18 US disclosed
US-20120203030-A1 PHOTOACID GENERATOR, METHOD FOR PRODUCING THE SAME, AND RESIST COMPOSITION COMPRISING THE SAME KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) 2012-08-09 US disclosed
WO-1996038435-A1 DOPAMINE AGONISTS ABBOTT LABORATORIES (US) 1996-12-05 WO disclosed
EP-0474767-B1 DOPAMINE AGONISTS ABBOTT LAB (US) 1996-02-21 EP disclosed
EP-0665215-A1 1,4-Diamino-2,3-dihydroxybutanes THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1995-08-02 EP disclosed
US-5430155-A Viricides, treatment of AIDS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1995-07-04 US disclosed
US-5294720-A Viricides THE DUPONT MERCK PHARMACEUTICAL CO. (US) 1994-03-15 US disclosed
EP-0532693-A1 1,4-DIAMINO-2,3-DIHYDROXYBUTANES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1993-03-24 EP disclosed
WO-1991018866-A2 1,4-DIAMINO-2,3-DIHYDROXYBUTANES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1991-12-12 WO disclosed
WO-1990015056-A1 DOPAMINE AGONISTS ABBOTT LABORATORIES (US) 1990-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120203030-A1 PHOTOACID GENERATOR, METHOD FOR PRODUCING THE SAME, AND RESIST COMPOSITION COMPRISING THE SAME ARF1, ARFGAP1, RALA CYP2C9 1706/4885CYP2A13 1065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.